

The peroxisomal transporter ABCD3 plays a major role in dicarboxylic fatty acid metabolism

Pablo Ranea-Robles, Hongjie Chen, Brandon Stauffer, Chunli Yu, Dipankar Bhattacharya,

Scott L. Friedman, Michelle Puchowicz, Sander M. Houten

Supplemental information Table of Contents

Supplementary Figure legend

Supplementary Figure S1. Characterization of a second *Abcd3* KO mouse

Supplementary Figure S2. Urinary DCA alterations in *Abcd3* KO mice

Supplementary Figure S3. DCA metabolism alterations in *Abcd3* KO mice

Supplementary Tables

Supplementary Table S1. Genotype distribution in a cross of *Abcd3*^{+/-} x *Abcd3*^{+/-} mice


Supplementary Table S2. Plasma bile acid concentrations in *Abcd3* KO fed mice

Supplementary Table S3. Untargeted metabolomics dataset comparing WT and *Abcd3* KO liver


Supplementary Table S4. Urinary DCA, and plasma and hepatic acylcarnitine concentrations in WT and *Abcd3* KO mice.

Supplementary Figures


Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3



Supplementary Figure Legends

Figure S1. Characterization of a second *Abcd3* KO mouse

A) Representative images of H & E staining of WT and *Abcd3* KO livers from male fasted mice. Scale bar = 100 μ m. **B)** Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities (in U/L) in WT and *Abcd3* KO plasma (n=4). **C)** Representative images of H & E staining of an *Abcd3* KO liver that presented nodules with vesicular steatosis and inflammatory infiltrates. Scale bar = 100 μ m. **E)** Blood glucose levels (in mM). **F)** Non-esterified fatty acids (NEFA) levels (in mM) in plasma. **G)** Total glycerol levels (in mM) in plasma. **H)** Epididymal white adipose tissue (eWAT) pad mass (as the % of body weight). BW: body weight. **I)** Lean mass (in %) as measured by echoMRI. **J)** Fat mass (in %) as measured by echoMRI. **K)** Total cholesterol levels (in mM) in plasma. **L)** Beta-hydroxybutyrate (β -OHB) levels (in mM) in plasma. **M)** Representative immunofluorescent images using an antibody against EHHADH to label peroxisomes in WT and *Abcd3* KO liver sections. Scale bar = 100 μ m. Individual values, the average and the standard deviation are graphed for each parameter.* p<0.05; ** p<0.01; *** p<0.001 (unpaired, two-tailed student t-test in B, I, J; two-way ANOVA in E-H, and K-L). G: Genotype; F: Feeding; I: Interaction.

Figure S2. Urinary DCA alterations in *Abcd3* KO mice

A) Urinary C6-DCA, C8-DCA, C10-DCA, and C12-DCA (in mmol/mol creatinine) in fasted WT (n=5 males, n=5 females) and *Abcd3* KO (n=7 males, n=8 females) mice. **B)** Urinary 3-OH DCAs (C6-, C8-, C10-, and C12-, in mmol/mol creatinine) in WT (n=4 males, n=4 females) and *Abcd3* KO (n=6 males, n=5 females) fed mice. **C)** Urinary 3-OH DCAs (C6-, C8-, C10-, and C12-, in mmol/mol creatinine) in WT (n=5 males, n=5 females) and *Abcd3* KO (n=7 males, n=8 females) fasted mice. Individual values, the average and the standard deviation are graphed for each parameter.* p<0.05; ** p<0.01; *** p<0.001 (two-way ANOVA). The effects in the two-way ANOVA are abbreviated as follows: G: Genotype; S: Sex; I: Interaction.

Figure S3. DCA metabolism alterations in *Abcd3* KO mice

A) Plasma short- and medium-chain dicarboxylcarnitine profile (in $\mu\text{mol/L}$) in fed and fasted WT and *Abcd3* KO mice (n=5 per genotype and feeding condition). **B)** Plasma free carnitine (C0) and acetylcarnitine (C2) levels (in $\mu\text{mol/L}$) in fed and fasted WT and *Abcd3* KO mice (n=5 per genotype and feeding condition). **C)** Liver free carnitine (C0) and acetylcarnitine (C2) levels (in pmol/mg tissue) in WT (n=5 fed, n=7 fasted) and *Abcd3* KO (n=5 fed, n=7 fasted) mice. **D)** Plasma short-chain acylcarnitine profile (in $\mu\text{mol/L}$) in fed and fasted WT and *Abcd3* KO mice (n=5 per genotype and feeding condition). **E)** Liver short-chain acylcarnitine profile (in pmol/mg tissue) in WT (n=5 fed, n=7 fasted) and *Abcd3* KO (n=5 fed, n=7 fasted) mice. **F)** Plasma medium- and long-chain acylcarnitine profile (in $\mu\text{mol/L}$) in fed and fasted WT and *Abcd3* KO mice (n=5 per genotype and feeding condition). **G)** Measured [^{13}C]-labeled C10-DC-carnitine (in $\mu\text{mol/L}$) in media of mouse liver slices after 4-hr incubation of WT and *Abcd3* KO mouse liver slices (n=4) with [^{13}C]-C12-DCA alone or with [^{13}C]-C12-DCA + L-aminocarnitine (L-AC). **H)** Urinary even-chain DCAs (C6- to C14-, in mmol/mol creatinine) in WT (n=10 vehicle, n=5 L-AC) and *Abcd3* KO (n=15 vehicle, n=3 L-AC) mice injected with vehicle or L-aminocarnitine and subjected to overnight food withdrawal. **I)** Urinary even-chain 3-OH-DCAs (C6- to C12-, in mmol/mol creatinine) in WT (n=10 vehicle, n=5 L-AC) and *Abcd3* KO (n=15 vehicle, n=3 L-AC) mice injected with vehicle or L-AC and subjected to overnight food withdrawal. Individual values, the average and the standard deviation are graphed. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ (two-way ANOVA). The effects in the two-way ANOVA are abbreviated as follows: G: Genotype; F: Feeding; L: L-AC; I: Interaction.